These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 22509934)

  • 81. Anti-PSMA/CD3 Bispecific Antibody Delivery and Antitumor Activity Using a Polymeric Depot Formulation.
    Leconet W; Liu H; Guo M; Le Lamer-Déchamps S; Molinier C; Kim S; Vrlinic T; Oster M; Liu F; Navarro V; Batra JS; Noriega AL; Grizot S; Bander NH
    Mol Cancer Ther; 2018 Sep; 17(9):1927-1940. PubMed ID: 29891487
    [TBL] [Abstract][Full Text] [Related]  

  • 82. T-Cell redirecting bispecific antibodies: a review of a novel class of immuno-oncology for advanced prostate cancer.
    Palecki J; Bhasin A; Bernstein A; Mille PJ; Tester WJ; Kelly WK; Zarrabi KK
    Cancer Biol Ther; 2024 Dec; 25(1):2356820. PubMed ID: 38801069
    [TBL] [Abstract][Full Text] [Related]  

  • 83. In vitro synthesis of primary specific anti-breast cancer antibodies by normal human peripheral blood mononuclear cells.
    Thakur A; Norkina O; Lum LG
    Cancer Immunol Immunother; 2011 Dec; 60(12):1707-20. PubMed ID: 21713642
    [TBL] [Abstract][Full Text] [Related]  

  • 84. A-Disintegrin and Metalloproteinase (ADAM) 17 Enzymatically Degrades Interferon-gamma.
    Kanzaki H; Shinohara F; Suzuki M; Wada S; Miyamoto Y; Yamaguchi Y; Katsumata Y; Makihira S; Kawai T; Taubman MA; Nakamura Y
    Sci Rep; 2016 Aug; 6():32259. PubMed ID: 27573075
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Cytotoxic enhancement of a bispecific diabody by format conversion to tandem single-chain variable fragment (taFv): the case of the hEx3 diabody.
    Asano R; Ikoma K; Shimomura I; Taki S; Nakanishi T; Umetsu M; Kumagai I
    J Biol Chem; 2011 Jan; 286(3):1812-8. PubMed ID: 21097496
    [TBL] [Abstract][Full Text] [Related]  

  • 86. GLP toxicology study of a fully-human T cell redirecting CD3:EGFRvIII binding immunotherapeutic bispecific antibody.
    Gedeon PC; Streicker MA; Schaller TH; Archer GE; Jokinen MP; Sampson JH
    PLoS One; 2020; 15(7):e0236374. PubMed ID: 32735564
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Preclinical Assessment of a MUC12-Targeted BiTE (Bispecific T-cell Engager) Molecule.
    Pham E; Friedrich M; Aeffner F; Lutteropp M; Mariano NF; Deegen P; Dahlhoff C; Vogel F; Bluemel C; Harrold JM; Brandl C; Grinberg N; Rattel B; Coxon A; Bailis JM
    Mol Cancer Ther; 2021 Oct; 20(10):1977-1987. PubMed ID: 34376583
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Therapeutic Bispecific T-Cell Engager Antibody Targeting the Transferrin Receptor.
    Fu M; He Q; Guo Z; Zhou X; Li H; Zhao L; Tang H; Zhou X; Zhu H; Shen G; He Y; Lei P
    Front Immunol; 2019; 10():1396. PubMed ID: 31293575
    [TBL] [Abstract][Full Text] [Related]  

  • 89. A Pronectin™ AXL-targeted first-in-class bispecific T cell engager (pAXLxCD3ε) for ovarian cancer.
    Riillo C; Polerà N; Di Martino MT; Juli G; Hokanson CA; Odineca T; Signorelli S; Grillone K; Ascrizzi S; Mancuso A; Staropoli N; Caparello B; Cerra M; Nisticò G; Tagliaferri P; Crea R; Caracciolo D; Tassone P
    J Transl Med; 2023 May; 21(1):301. PubMed ID: 37143061
    [TBL] [Abstract][Full Text] [Related]  

  • 90. In vitro toxicological support to establish specification limit for anti-CD3 monospecific impurity in a bispecific T cell engager drug, ERY974.
    Harada A; Shioda A; Ikuno T; Iwata Y; Shiraiwa H; Wakabayashi T; Sano Y; Mishima M
    Toxicol In Vitro; 2020 Aug; 66():104841. PubMed ID: 32247040
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Highly flexible, IgG-shaped, trivalent antibodies effectively target tumor cells and induce T cell-mediated killing.
    Dickopf S; Lauer ME; Ringler P; Spick C; Kern P; Brinkmann U
    Biol Chem; 2019 Feb; 400(3):343-350. PubMed ID: 30763031
    [TBL] [Abstract][Full Text] [Related]  

  • 92. PSMA-targeted bispecific Fab conjugates that engage T cells.
    Patterson JT; Isaacson J; Kerwin L; Atassi G; Duggal R; Bresson D; Zhu T; Zhou H; Fu Y; Kaufmann GF
    Bioorg Med Chem Lett; 2017 Dec; 27(24):5490-5495. PubMed ID: 29126850
    [TBL] [Abstract][Full Text] [Related]  

  • 93. A trispecific antibody induces potent tumor-directed T-cell activation and antitumor activity by CD3/CD28 co-engagement.
    Chen L; Qian W; Pan F; Li D; Yu W; Tong L; Yang Y; Xu Q; Ding J; Dai R; Xian W; Zhu X; Ren P; Zhu H
    Immunotherapy; 2024 Feb; 16(3):143-159. PubMed ID: 38126157
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Role of ADAM17 in the non-cell autonomous effects of oncogene-induced senescence.
    Morancho B; Martínez-Barriocanal Á; Villanueva J; Arribas J
    Breast Cancer Res; 2015 Aug; 17(1):106. PubMed ID: 26260680
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Functional analysis of bispecific antibody (EpCAMxCD3)-mediated T-lymphocyte and cancer cell interaction by single-cell force spectroscopy.
    Hoffmann SC; Wabnitz GH; Samstag Y; Moldenhauer G; Ludwig T
    Int J Cancer; 2011 May; 128(9):2096-104. PubMed ID: 20635391
    [TBL] [Abstract][Full Text] [Related]  

  • 96. A simplified function-first method for the discovery and optimization of bispecific immune engaging antibodies.
    Shepherd A; Bennychen B; Marcil A; Bloemberg D; Pon RA; Weeratna RD; McComb S
    PLoS One; 2023; 18(6):e0273884. PubMed ID: 37347762
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Single domain based bispecific antibody, Muc1-Bi-1, and its humanized form, Muc1-Bi-2, induce potent cancer cell killing in muc1 positive tumor cells.
    Li Y; Zhou C; Li J; Liu J; Lin L; Li L; Cao D; Li Q; Wang Z
    PLoS One; 2018; 13(1):e0191024. PubMed ID: 29357376
    [TBL] [Abstract][Full Text] [Related]  

  • 98. A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo.
    Hipp S; Tai YT; Blanset D; Deegen P; Wahl J; Thomas O; Rattel B; Adam PJ; Anderson KC; Friedrich M
    Leukemia; 2017 Aug; 31(8):1743-1751. PubMed ID: 28025583
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Development of an antibody-like T-cell engager based on VH-VL heterodimer formation and its application in cancer therapy.
    Jang S; Song J; Kim N; Bak J; Jung K; Park YW; Park BC; Kim HM
    Biomaterials; 2021 Apr; 271():120760. PubMed ID: 33774526
    [TBL] [Abstract][Full Text] [Related]  

  • 100. The synthesis of amphiphilic polyethyleneimine/calcium phosphate composites for bispecific T-cell engager based immunogene therapy.
    Chen P; Liu Y; Zhao J; Pang X; Zhang P; Hou X; Chen P; He CY; Wang Z; Chen ZY
    Biomater Sci; 2018 Feb; 6(3):633-641. PubMed ID: 29411792
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.